Skip to main content
Top
Published in: Urolithiasis 3/2019

01-06-2019 | Original Paper

Testing the dogma that total phospholipid fatty acid composition of blood plays a role in kidney stone pathogenesis, using a high–low risk human model: results from a pilot study

Authors: Allen L. Rodgers, Dalielah Jappie-Mahomed, Paul J. van Jaarsveld

Published in: Urolithiasis | Issue 3/2019

Login to get access

Abstract

Previous studies have suggested that ω-3 and ω-6 polyunsaturated fatty acid (PUFA) composition in plasma and red blood cell (RBC) total phospholipids plays a role in urolithiasis. Our aim was to test the robustness of this dogma by retrospectively comparing baseline profiles of these parameters in subjects from high- and low-stone-risk groups. The documented difference in stone occurrence in white (relatively common) (W) and black (rare) (B) subjects prompted us to select these groups as the high–low risk model for the study. Blood and urine samples were obtained from ten subjects in each group and were analysed for PUFAs and stone risk factors, respectively. Concentrations of linoleic acid (LA), eicosadienoic acid (EDA) and arachidonic acid (AA) in plasma and or/RBC total phospholipids were significantly higher in B. Differences in other PUFA profiles were also observed. There was no inter-group difference in AA/LA ratios. Urinary oxalate was significantly higher while urinary phosphate was significantly lower in B. We speculate that elevated AA in B might arise because of a possibly enhanced elongation of LA to EDA, as well as an enhanced ∆-8-desaturation of EDA to dihomo-gamma-linolenic acid (DGLA), which is the immediate precursor of AA. Alternatively, we speculate that the ∆-5-desaturation step of DGLA to AA might be more highly activated in this group. Irrespective of the mechanism, our observed inter-group differences in phospholipid PUFA composition are in conflict with previously published dogma which relates PUFA characteristics to high- and low-stone risk.
Literature
1.
go back to reference Baggio B, Gambaro G, Zambon S, Marchini F, Bassi A, Manzato E (1996) Anomalous phospholipid n-6 polyunsaturated fatty acid composition in idiopathic calcium nephrolithiasis. J Am Soc Nephrol 7(4):613–620PubMed Baggio B, Gambaro G, Zambon S, Marchini F, Bassi A, Manzato E (1996) Anomalous phospholipid n-6 polyunsaturated fatty acid composition in idiopathic calcium nephrolithiasis. J Am Soc Nephrol 7(4):613–620PubMed
2.
go back to reference Baggio B, Budakovic A, Nassuato MA, Vezzoli G, Manzato E, Luisetto G, Zaninotto M (2000) Plasma phospholipid arachidonic acid content and calcium metabolism in idiopathic calcium nephroloithiasis. Kidney Int 58:1278–1284CrossRefPubMed Baggio B, Budakovic A, Nassuato MA, Vezzoli G, Manzato E, Luisetto G, Zaninotto M (2000) Plasma phospholipid arachidonic acid content and calcium metabolism in idiopathic calcium nephroloithiasis. Kidney Int 58:1278–1284CrossRefPubMed
3.
go back to reference Buck AC, Davies R, Harrison T (1991) The protective role of eicosapantaenoic acid (EPA) in the pathogenesis of nephrolithiasis. J Urol 146:188–194CrossRefPubMed Buck AC, Davies R, Harrison T (1991) The protective role of eicosapantaenoic acid (EPA) in the pathogenesis of nephrolithiasis. J Urol 146:188–194CrossRefPubMed
4.
go back to reference Buck AC, Lote CJ, Sampson WF (1983) The influence of renal prostaglandins on urinary calcium excretion in idiopathic urolithiasis. J Urol 129(2):421–426CrossRefPubMed Buck AC, Lote CJ, Sampson WF (1983) The influence of renal prostaglandins on urinary calcium excretion in idiopathic urolithiasis. J Urol 129(2):421–426CrossRefPubMed
5.
go back to reference Baggio B, Gambaro G (1993) Abnormal arachidonic acid content of membrane phospholipids—the unifying hypothesis for the genesis of hypercalciuria and hyperoxaluria in idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 14(3):553–555CrossRef Baggio B, Gambaro G (1993) Abnormal arachidonic acid content of membrane phospholipids—the unifying hypothesis for the genesis of hypercalciuria and hyperoxaluria in idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 14(3):553–555CrossRef
6.
go back to reference Baggio B, Gambaro G, Marchini F, Cicerello E, Borsatti A (1984) Raised transmembrane oxalate flux in red blood cells in idiopathic calcium oxalate nephrolithiasis. Lancet 324(8393):12–13CrossRef Baggio B, Gambaro G, Marchini F, Cicerello E, Borsatti A (1984) Raised transmembrane oxalate flux in red blood cells in idiopathic calcium oxalate nephrolithiasis. Lancet 324(8393):12–13CrossRef
7.
go back to reference Naya Y, Ito H, Masai M, Yamaguchi K (2002) Association of dietary fatty acids with urinary oxalate excretion in calcium oxalate stone-formers in their fourth decade. BJU Int 89(9):842–846CrossRefPubMed Naya Y, Ito H, Masai M, Yamaguchi K (2002) Association of dietary fatty acids with urinary oxalate excretion in calcium oxalate stone-formers in their fourth decade. BJU Int 89(9):842–846CrossRefPubMed
8.
go back to reference Taylor EN, Stampfer MJ, Curhan GC (2005) Fatty acid intake and incident nephrolithiasis. Am J Kidney Dis 45:267–274CrossRefPubMed Taylor EN, Stampfer MJ, Curhan GC (2005) Fatty acid intake and incident nephrolithiasis. Am J Kidney Dis 45:267–274CrossRefPubMed
9.
go back to reference Siener R, Jansen B, Watzer B, Hesse A (2011) Effect of n-3 fatty acid supplementation on urinary risk factors for calcium oxalate stone formation. J Urol 185:719–724CrossRefPubMed Siener R, Jansen B, Watzer B, Hesse A (2011) Effect of n-3 fatty acid supplementation on urinary risk factors for calcium oxalate stone formation. J Urol 185:719–724CrossRefPubMed
10.
go back to reference Buck AC, Smellie WS, Jenkins A, Meddings R, James A, Horrobin D (1994) The treatment of idiopathic recurrent urolithiasis with fish oil and evening primrose oil—a double-blind study. In: Ryall R et al (eds) Urolithiasis 2. Plenum Press, New York, pp 575–580CrossRef Buck AC, Smellie WS, Jenkins A, Meddings R, James A, Horrobin D (1994) The treatment of idiopathic recurrent urolithiasis with fish oil and evening primrose oil—a double-blind study. In: Ryall R et al (eds) Urolithiasis 2. Plenum Press, New York, pp 575–580CrossRef
11.
go back to reference Rothwell PJ, Green R, Blacklock NJ, Kavanagh JP (1993) Does fish oil benefit stone formers? J Urol 150:1391–1394CrossRefPubMed Rothwell PJ, Green R, Blacklock NJ, Kavanagh JP (1993) Does fish oil benefit stone formers? J Urol 150:1391–1394CrossRefPubMed
12.
go back to reference Messa P, Londero D, Massarino F, Paganin L, Mioni G, Zattoni F, Cannella G (2000) Abnormal arachidonic acid content of red blood cell membranes and main lithogenic factors in stone formers. Nephrol Dial Transplant 15:1388–1393CrossRefPubMed Messa P, Londero D, Massarino F, Paganin L, Mioni G, Zattoni F, Cannella G (2000) Abnormal arachidonic acid content of red blood cell membranes and main lithogenic factors in stone formers. Nephrol Dial Transplant 15:1388–1393CrossRefPubMed
13.
go back to reference Whalley NA, Moraes MF, Shar TG, Pretorius SS, Meyers AM (1998) Lithogenic risk factors in the urine of black and white controls. Br J Urol 82(6):785–790CrossRefPubMed Whalley NA, Moraes MF, Shar TG, Pretorius SS, Meyers AM (1998) Lithogenic risk factors in the urine of black and white controls. Br J Urol 82(6):785–790CrossRefPubMed
14.
go back to reference Rodgers A, Jappie-Mahomed, van Jaarsveld PJ (2017) Different effects of γ-linolenic acid (GLA) supplementation on plasma and red blood cell phospholipid fatty acid composition and calcium oxalate kidney stone risk factors in healthy subjects from two race groups with different risk profiles pose questions about the GLA-arachidonic acid-oxaluria metabolic pathway: pilot study. Urolithiasis. https://doi.org/10.1007/s00240-017-0989-7 CrossRefPubMed Rodgers A, Jappie-Mahomed, van Jaarsveld PJ (2017) Different effects of γ-linolenic acid (GLA) supplementation on plasma and red blood cell phospholipid fatty acid composition and calcium oxalate kidney stone risk factors in healthy subjects from two race groups with different risk profiles pose questions about the GLA-arachidonic acid-oxaluria metabolic pathway: pilot study. Urolithiasis. https://​doi.​org/​10.​1007/​s00240-017-0989-7 CrossRefPubMed
15.
go back to reference Wolmarans P, Humpreys J, Sayed N (2002) Foodfinder™ 2. Nutritional Intervention Unit, South African Medical Research Council, Cape Town Wolmarans P, Humpreys J, Sayed N (2002) Foodfinder™ 2. Nutritional Intervention Unit, South African Medical Research Council, Cape Town
16.
go back to reference Folch J, Lees M, Sloane-Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509 Folch J, Lees M, Sloane-Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509
17.
go back to reference Hon G, Hassan M, van Rensburg SJ, Abel S, Marais DW, van Jaarsveld P, Smuts C, Henning F, Erasmus R, Matsha T (2009) Immune cell membrane fatty acids and inflammatory marker, C-reactive protein, in patients with multiple sclerosis. Br J Nutr 102:1334–1340CrossRefPubMed Hon G, Hassan M, van Rensburg SJ, Abel S, Marais DW, van Jaarsveld P, Smuts C, Henning F, Erasmus R, Matsha T (2009) Immune cell membrane fatty acids and inflammatory marker, C-reactive protein, in patients with multiple sclerosis. Br J Nutr 102:1334–1340CrossRefPubMed
18.
go back to reference Van Jaarsveld PJ, Smuts CM, Tichelaar HY, Kruger M, Benadé AJ (2000) Effect of palm oil on plasma lipoprotein concentrations and plasma low-density lipoprotein composition in non-human primates. Int J Food Sci Nutr 51(Suppl):S21–S30CrossRefPubMed Van Jaarsveld PJ, Smuts CM, Tichelaar HY, Kruger M, Benadé AJ (2000) Effect of palm oil on plasma lipoprotein concentrations and plasma low-density lipoprotein composition in non-human primates. Int J Food Sci Nutr 51(Suppl):S21–S30CrossRefPubMed
19.
go back to reference Allie-Hamdulay S, Rodgers A (2005) Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial. Urol Res 33:116–124CrossRefPubMed Allie-Hamdulay S, Rodgers A (2005) Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial. Urol Res 33:116–124CrossRefPubMed
20.
go back to reference Tiselius HG (1982) An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122:409–418CrossRefPubMed Tiselius HG (1982) An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122:409–418CrossRefPubMed
21.
go back to reference Werness PG, Brown CM, Smith LH, Finlayson B (1985) Equil 2: a basic computer program for the calculation of urinary saturation. J Urol 134:1242–1244CrossRefPubMed Werness PG, Brown CM, Smith LH, Finlayson B (1985) Equil 2: a basic computer program for the calculation of urinary saturation. J Urol 134:1242–1244CrossRefPubMed
22.
go back to reference Park WJ, Kothapalli KS, Lawrence P, Tyburczy C, Brenna JT (2009) An alternate pathway to long chain polyunsaturates: the FADS2 gene product ∆8-desaturates 20:2n-6 and 20:3n-3. J Lipid Res 50:1195–1202CrossRefPubMedPubMedCentral Park WJ, Kothapalli KS, Lawrence P, Tyburczy C, Brenna JT (2009) An alternate pathway to long chain polyunsaturates: the FADS2 gene product ∆8-desaturates 20:2n-6 and 20:3n-3. J Lipid Res 50:1195–1202CrossRefPubMedPubMedCentral
23.
go back to reference Brenna JT, Kothapalli KS, Park WJ (2010) Alternative transcripts of fatty acid desaturase (FADS) genes. Prostaglandins Leukot Essent Fatty Acids 82:281–285CrossRefPubMedPubMedCentral Brenna JT, Kothapalli KS, Park WJ (2010) Alternative transcripts of fatty acid desaturase (FADS) genes. Prostaglandins Leukot Essent Fatty Acids 82:281–285CrossRefPubMedPubMedCentral
24.
go back to reference Nouvenne A, Meschi T, Guerra A, Allegri F, Prati B, Borghi L (2008) Dietary treatment of nephrolithiasis. Clin Cases Miner Bone Metab 5:135–141PubMedPubMedCentral Nouvenne A, Meschi T, Guerra A, Allegri F, Prati B, Borghi L (2008) Dietary treatment of nephrolithiasis. Clin Cases Miner Bone Metab 5:135–141PubMedPubMedCentral
25.
go back to reference Curhan GC (1993) A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328:833–838CrossRefPubMed Curhan GC (1993) A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328:833–838CrossRefPubMed
Metadata
Title
Testing the dogma that total phospholipid fatty acid composition of blood plays a role in kidney stone pathogenesis, using a high–low risk human model: results from a pilot study
Authors
Allen L. Rodgers
Dalielah Jappie-Mahomed
Paul J. van Jaarsveld
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Published in
Urolithiasis / Issue 3/2019
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-018-1071-9

Other articles of this Issue 3/2019

Urolithiasis 3/2019 Go to the issue